# Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

> **NCT06589440** · PHASE2 · RECRUITING · sponsor: **Stingray Therapeutics** · enrollment: 70 (estimated)

## Conditions studied

- Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

## Interventions

- **DRUG:** SR-8541A

## Key facts

- **NCT ID:** NCT06589440
- **Lead sponsor:** Stingray Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06589440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06589440, "Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06589440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*